γ-Aminobutyric acid type B receptor changes in the rat striatum and substantia nigra following intrastriatal quinolinic acid lesions

Journal of Neuroscience Research

Volumn 89, Issue 4, 2011, Pages 524-535

  Rekik, Letaïef ^a,b   Daguin Nerrière, Véronique ^b   Petit, Jean Yves ^b   Brachet, Philippe ^b  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

Basal ganglia; GABA; Huntington's disease; Immunohistochemistry; Metabotropic receptors

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; QUINOLINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN DAMAGE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; STELLATE CELL; SUBSTANTIA NIGRA PARS COMPACTA;

ANIMALS; ASTROCYTES; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; FEMALE; HUNTINGTON DISEASE; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENTRICULAR; QUINOLINIC ACID; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-B; SUBSTANTIA NIGRA;

EID: 79751475463     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22574     Document Type: Article

References (47)

1. Arzberger T, Krampfl K, Leimgruber S, Weindl A. 1997. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease-an in situ hybridization study. J Neuropathol Exp Neurol 56: 440-454.
2. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. 1986. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321: 168-171.
3. B receptors. Pharmacol Ther 110: 533-543.
4. Block F, Schwarz M. 1994. Expression of GFAP in the striatum and its projection areas in response to striatal quinolinic acid lesion in rats. Neuroreport 5: 2237-2240.
5. Block F, Loos M, Frohn C, Schwarz M. 2004. Association between inflammation and nigral neuronal damage following striatal excitotoxic lesion. Brain Res 998: 29-35.
6. Bowery NG, Enna SJ. 2000. Gamma-aminobutyric acid(B) receptors: first of the functional metabotropic heterodimers. J Pharmacol Exp Ther 292: 2-7.
7. B receptor: a site of therapeutic benefit. Curr Opin Pharmacol 6: 37-43.
8. B receptor subunits in the rat substantia nigra. Eur J Neurosci 18: 3279-3293.
9. Boyes J, Bolam JP. 2007. Localization of GABA receptors in the basal ganglia. Prog Brain Res 160: 229-243.
10. A receptor changes. J Chem Neuroanat 17: 75-97.
11. B receptors in the basal ganglia in monkeys. Neuroscience 95: 127-140.
12. B R1 receptor distribution. J Comp Neurol 476: 65-79.
13. B2 subunits in rat brain, spinal cord and dorsal root ganglion. Neuroscience 106: 447-467.
14. B receptor subunit expression in glia. Mol Cell Neurosci 24: 214-223.
15. B receptor subunits in rat globus pallidus. J Comp Neurol 474: 340-352.
16. B receptors: structure and function. Prog Brain Res 160: 43-57.
17. Fine SM, Angel RA, Perry SW, Epstein LG, Rothstein JD, Dewhurst S, Gelbard HA. 1996. Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia. J Biol Chem 271: 15303-15306.
18. B receptor antagonist in clinical trials. Biochem Pharmacol 68: 1479-1487.
19. A receptor subunits in the substantia nigra of the rat: effects of quinolinic acid lesions of the striatum. Eur J Neurosci 15: 1961-1975.
20. Galvan A, Wichmann T. 2007. GABAergic circuits in the basal ganglia and movement disorders. Prog Brain Res 160: 287-312.
21. Gentilini G, Franchi-Micheli S, Mugnai S, Bindi D, Zilletti L. 1995. GABA-mediated inhibition of the anaphylactic response in the guinea-pig trachea. Br J Pharmacol 115: 389-394.
22. Gonzalez I, Arevalo-Serrano J, Perez JL, Gonzalo P, Gonzalo-Ruiz A. 2008. Effects of beta-amyloid peptide on the density of M2 muscarinic acetylcholine receptor protein in the hippocampus of the rat: relationship with GABA-, calcium-binding protein and somatostatin-containing cells. Neuropathol Appl Neurobiol 34: 506-522.
23. Huang CS, Shi SH, Ule J, Ruggiu M, Barker LA, Darnell RB, Jan YN, Jan LY. 2005. Common molecular pathways mediate long-term potentiation of synaptic excitation and slow synaptic inhibition. Cell 123: 105-118.
24. Isacson O, Fischer W, Wictorin K, Dawbarn D, Bjorklund A. 1987. Astroglial response in the excitotoxically lesioned neostriatum and its projection areas in the rat. Neuroscience 20: 1043-1056.
25. BR1 subunit expression in Alzheimer's patients: association with Braak staging. Acta Neuropathol 109: 467-474.
26. B receptors uncovers similarity to metabotropic glutamate receptors. Nature 386: 239-246.
27. B-receptor subtypes assemble into functional heteromeric complexes. Nature 396: 683-687.
28. Kawaguchi Y, Wilson CJ, Augood SJ, Emson PC. 1995. Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci 18: 527-535.
29. Kettenmann H, Schachner M. 1985. Pharmacological properties of gamma-aminobutyric acid-, glutamate-, and aspartate-induced depolarizations in cultured astrocytes. J Neurosci 5: 3295-3301.
30. B receptors and synaptic modulation. Cell Tissue Res 326: 517-533.
31. Krammer EB. 1980. Anterograde and transsynaptic degeneration "en cascade" in basal ganglia induced by intrastriatal injection of kainic acid: an animal analogue of Huntington's disease. Brain Res 196: 209-221.
32. B receptors to modulate interleukin release. Mol Cell Neurosci 25: 312-322.
33. B2 receptor mRNAs in the rat brain. Mol Cells 16: 40-47.
34. Lievens JC, Woodman B, Mahal A, Spasic-Boscovic O, Samuel D, Kerkerian-Le Goff L, Bates GP. 2001. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol Dis 8: 807-821.
35. B receptor agonist, dose-dependently impairs spatial learning in rats. Pharmacol Biochem Behav 53: 303-308.
36. Menei P, Pean JM, Nerriere-Daguin V, Jollivet C, Brachet P, Benoit JP. 2000. Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage. Exp Neurol 161: 259-272.
37. Aalpha1 receptor immunoreactivity in the rat substantia nigra. Neuroscience 99: 65-76.
38. BR2 receptor immunoreactivity in neurochemically identified neurons of the rat neostriatum. J Comp Neurol 433: 458-470.
39. BR2 receptor immunoreactivity. Brain Res 920: 210-216.
40. A receptor subtype changes in the substantia nigra of the rat following quinolinate lesions in the striatum: a correlative in situ hybridization and immunohistochemical study. Neuroscience 74: 89-98.
41. B receptors in primary cultures of astrocytes from rat cerebral cortex. Biochem Biophys Res Commun 341: 874-881.
42. Ouimet CC, Greengard P. 1990. Distribution of DARPP-32 in the basal ganglia: an electron microscopic study. J Neurocytol 19: 39-52.
43. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates. New York: Academic Press.
44. Saji M, Reis DJ. 1987. Delayed transneuronal death of substantia nigra neurons prevented by gamma-aminobutyric acid agonist. Science 235: 66-69.
45. Topper R, Gehrmann J, Schwarz M, Block F, Noth J, Kreutzberg GW. 1993. Remote microglial activation in the quinolinic acid model of Huntington's disease. Exp Neurol 123: 271-283.
46. BR2 receptor subunits. J Comp Neurol 470: 339-356.
47. Ye ZC, Sontheimer H. 1996. Cytokine modulation of glial glutamate uptake: a possible involvement of nitric oxide. Neuroreport 7: 2181-2185.